Zacks Research Issues Optimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Stock analysts at Zacks Research raised their Q2 2026 earnings estimates for Corcept Therapeutics in a report released on Wednesday, April 2nd. Zacks Research analyst K. Das now forecasts that the biotechnology company will earn $0.68 per share for the quarter, up from their prior estimate of $0.67. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q3 2026 earnings at $0.83 EPS, Q4 2026 earnings at $0.91 EPS, FY2026 earnings at $2.89 EPS, Q1 2027 earnings at $0.59 EPS and FY2027 earnings at $3.75 EPS.

A number of other equities analysts have also weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Truist Financial upped their price target on Corcept Therapeutics from $76.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 31st. StockNews.com cut Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Piper Sandler upped their target price on Corcept Therapeutics from $128.00 to $131.00 and gave the company an "overweight" rating in a report on Thursday, April 3rd. Finally, HC Wainwright raised their target price on Corcept Therapeutics from $115.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $143.25.

Remove Ads

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics stock traded up $1.90 during trading hours on Friday, reaching $72.39. 990,600 shares of the company's stock were exchanged, compared to its average volume of 1,108,303. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $117.33. The company has a market capitalization of $7.64 billion, a P/E ratio of 57.99 and a beta of 0.15. The business has a fifty day moving average of $65.48 and a two-hundred day moving average of $57.03. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.11). The firm had revenue of $181.89 million for the quarter, compared to analyst estimates of $200.12 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%.

Insiders Place Their Bets

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Friday, January 10th. The stock was sold at an average price of $50.54, for a total value of $111,188.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph K. Belanoff sold 2,924 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $60.91, for a total value of $178,100.84. Following the transaction, the chief executive officer now directly owns 3,019,411 shares in the company, valued at approximately $183,912,324.01. The trade was a 0.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 163,124 shares of company stock valued at $15,074,318 over the last 90 days. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Several large investors have recently added to or reduced their stakes in CORT. Vanguard Group Inc. grew its stake in shares of Corcept Therapeutics by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock worth $509,726,000 after acquiring an additional 109,294 shares in the last quarter. Parallel Advisors LLC grew its stake in Corcept Therapeutics by 3.7% during the 1st quarter. Parallel Advisors LLC now owns 3,972,416 shares of the biotechnology company's stock worth $453,729,000 after purchasing an additional 142,784 shares in the last quarter. State Street Corp grew its stake in Corcept Therapeutics by 0.6% during the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock worth $162,871,000 after purchasing an additional 19,893 shares in the last quarter. Geode Capital Management LLC increased its holdings in Corcept Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company's stock worth $110,108,000 after purchasing an additional 99,470 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its position in Corcept Therapeutics by 4.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company's stock valued at $82,889,000 after purchasing an additional 64,321 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.